Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Blocking the histone lysine 79 methyltransferase DOT1L alleviates renal fibrosis through inhibition of renal fibroblast activation and epithelial-mesenchymal transition.

Liu L, Zou J, Guan Y, Zhang Y, Zhang W, Zhou X, Xiong C, Tolbert E, Zhao TC, Bayliss G, Zhuang S.

FASEB J. 2019 Nov;33(11):11941-11958. doi: 10.1096/fj.201801861R. Epub 2019 Aug 2.

PMID:
31373855
2.

Application of nintedanib and other potential anti-fibrotic agents in fibrotic diseases.

Liu F, Bayliss G, Zhuang S.

Clin Sci (Lond). 2019 Jun 19;133(12):1309-1320. doi: 10.1042/CS20190249. Print 2019 Jun 28. Review.

PMID:
31217321
3.

TAVR in Patients With End-Stage Renal Disease and Critical Aortic Stenosis: Hard Choices.

Bayliss G.

J Am Coll Cardiol. 2019 Jun 11;73(22):2816-2818. doi: 10.1016/j.jacc.2019.04.007. No abstract available.

PMID:
31171087
4.

Selective inhibition of class IIa histone deacetylases alleviates renal fibrosis.

Xiong C, Guan Y, Zhou X, Liu L, Zhuang MA, Zhang W, Zhang Y, Masucci MV, Bayliss G, Zhao TC, Zhuang S.

FASEB J. 2019 Jul;33(7):8249-8262. doi: 10.1096/fj.201801067RR. Epub 2019 Apr 5.

PMID:
30951378
5.

Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan.

Chen DQ, Cao G, Chen H, Argyopoulos CP, Yu H, Su W, Chen L, Samuels DC, Zhuang S, Bayliss GP, Zhao S, Yu XY, Vaziri ND, Wang M, Liu D, Mao JR, Ma SX, Zhao J, Zhang Y, Shang YQ, Kang H, Ye F, Cheng XH, Li XR, Zhang L, Meng MX, Guo Y, Zhao YY.

Nat Commun. 2019 Apr 1;10(1):1476. doi: 10.1038/s41467-019-09329-0.

6.

A single-center analysis of early readmission after renal transplantation.

Kim SH, Baird GL, Bayliss G, Merhi B, Osband A, Gohh R, Morrissey PE.

Clin Transplant. 2019 May;33(5):e13520. doi: 10.1111/ctr.13520. Epub 2019 Mar 27.

PMID:
30861203
7.

Targeting Regulatory T Cells for Transplant Tolerance: New Insights and Future Perspectives.

Shaban E, Bayliss G, Malhotra DK, Shemin D, Wang LJ, Gohh R, Dworkin LD, Gong R.

Kidney Dis (Basel). 2018 Nov;4(4):205-213. doi: 10.1159/000490703. Epub 2018 Jul 31. Review.

8.

Targeting enhancer of zeste homolog 2 protects against acute kidney injury.

Zhou X, Zang X, Guan Y, Tolbert T, Zhao TC, Bayliss G, Zhuang S.

Cell Death Dis. 2018 Oct 19;9(11):1067. doi: 10.1038/s41419-018-1012-0.

9.

Kidney Transplant Outcomes in 2 Adults With Down Syndrome.

Henriksen KJ, Chang A, Bayliss GP.

Kidney Int Rep. 2018 Mar 2;3(4):979-984. doi: 10.1016/j.ekir.2018.02.006. eCollection 2018 Jul. No abstract available.

10.

Targeting histone methyltransferase enhancer of zeste homolog-2 inhibits renal epithelial-mesenchymal transition and attenuates renal fibrosis.

Zhou X, Xiong C, Tolbert E, Zhao TC, Bayliss G, Zhuang S.

FASEB J. 2018 May 18:fj201800237R. doi: 10.1096/fj.201800237R. [Epub ahead of print]

11.

Changes in treatment of hyperglycemia in a hypertensive type 2 diabetes population as renal function declines.

Weinrauch LA, Segal AR, Bayliss GP, Liu J, Wisniewski E, D'Elia JA.

Clin Kidney J. 2017 Oct;10(5):661-665. doi: 10.1093/ckj/sfx020. Epub 2017 May 25.

12.

Putting the "No" in Non Nocere: Surgery, Anesthesia, and a Patient's Right to Withdraw Consent.

Yee C, Himmelwright RS, Klyce W, Sankhla T, Bayliss GP.

R I Med J (2013). 2017 Oct 2;100(10):38-40.

PMID:
28968621
13.

Sodium-glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusions.

D'Elia JA, Segal AR, Bayliss GP, Weinrauch LA.

Int J Nephrol Renovasc Dis. 2017 Jun 15;10:153-158. doi: 10.2147/IJNRD.S135899. eCollection 2017.

14.

Proliferative glomerulonephritis with monoclonal IgG deposits in two kidney allografts successfully treated with rituximab.

Merhi B, Patel N, Bayliss G, Henriksen KJ, Gohh R.

Clin Kidney J. 2017 Jun;10(3):405-410. doi: 10.1093/ckj/sfx001. Epub 2017 Mar 22.

15.

Cholesterol Crystal Embolism and Chronic Kidney Disease.

Li X, Bayliss G, Zhuang S.

Int J Mol Sci. 2017 May 24;18(6). pii: E1120. doi: 10.3390/ijms18061120. Review.

16.

Pharmacological inhibition of Src kinase protects against acute kidney injury in a murine model of renal ischemia/reperfusion.

Xiong C, Zang X, Zhou X, Liu L, Masucci MV, Tang J, Li X, Liu N, Bayliss G, Zhao TC, Zhuang S.

Oncotarget. 2017 May 9;8(19):31238-31253. doi: 10.18632/oncotarget.16114.

17.

Cardiovascular-renal complications and the possible role of plasminogen activator inhibitor: a review.

D'Elia JA, Bayliss G, Gleason RE, Weinrauch LA.

Clin Kidney J. 2016 Oct;9(5):705-12. doi: 10.1093/ckj/sfw080. Epub 2016 Aug 31.

18.

Treating Hypertension in Diabetic Patients With Advanced Chronic Kidney Disease: What Should We Have in Mind?

Weinrauch LA, Bayliss G, Segal AR, Liu J, Wisniewski E, D'Elia JA.

J Clin Hypertens (Greenwich). 2016 Oct;18(10):1077-1078. doi: 10.1111/jch.12839. Epub 2016 May 11. No abstract available.

19.

Renal Function Alters Antihypertensive Regimens in Type 2 Diabetic Patients.

Weinrauch LA, Bayliss G, Segal AR, Liu J, Wisniewski E, D'Elia JA.

J Clin Hypertens (Greenwich). 2016 Sep;18(9):878-83. doi: 10.1111/jch.12776. Epub 2016 Mar 2.

20.

Role for urinary biomarkers in diagnosis of acute rejection in the transplanted kidney.

Merhi B, Bayliss G, Gohh RY.

World J Transplant. 2015 Dec 24;5(4):251-60. doi: 10.5500/wjt.v5.i4.251. Review.

21.

Enhancer of Zeste Homolog 2 Inhibition Attenuates Renal Fibrosis by Maintaining Smad7 and Phosphatase and Tensin Homolog Expression.

Zhou X, Zang X, Ponnusamy M, Masucci MV, Tolbert E, Gong R, Zhao TC, Liu N, Bayliss G, Dworkin LD, Zhuang S.

J Am Soc Nephrol. 2016 Jul;27(7):2092-108. doi: 10.1681/ASN.2015040457. Epub 2015 Dec 23. Erratum in: J Am Soc Nephrol. 2017 Jul;28(7):2252.

22.

Src inhibition blocks renal interstitial fibroblast activation and ameliorates renal fibrosis.

Yan Y, Ma L, Zhou X, Ponnusamy M, Tang J, Zhuang MA, Tolbert E, Bayliss G, Bai J, Zhuang S.

Kidney Int. 2016 Jan;89(1):68-81. doi: 10.1038/ki.2015.293. Epub 2016 Jan 4.

23.

Immunosuppression in the failing and failed transplant kidney: optimizing outcomes.

Kassakian CT, Ajmal S, Gohh RY, Morrissey PE, Bayliss GP.

Nephrol Dial Transplant. 2016 Aug;31(8):1261-9. doi: 10.1093/ndt/gfv256. Epub 2015 Jun 30. Review.

PMID:
26136481
24.

Developments in extracorporeal therapy for the poisoned patient.

Patel N, Bayliss GP.

Adv Drug Deliv Rev. 2015 Aug 1;90:3-11. doi: 10.1016/j.addr.2015.05.017. Epub 2015 Jun 5. Review.

PMID:
26050528
25.

Activation of Sirtuin-1 Promotes Renal Fibroblast Activation and Aggravates Renal Fibrogenesis.

Ponnusamy M, Zhuang MA, Zhou X, Tolbert E, Bayliss G, Zhao TC, Zhuang S.

J Pharmacol Exp Ther. 2015 Aug;354(2):142-51. doi: 10.1124/jpet.115.224386. Epub 2015 May 28.

26.

P2X7 receptor inhibition protects against ischemic acute kidney injury in mice.

Yan Y, Bai J, Zhou X, Tang J, Jiang C, Tolbert E, Bayliss G, Gong R, Zhao TC, Zhuang S.

Am J Physiol Cell Physiol. 2015 Mar 15;308(6):C463-72. doi: 10.1152/ajpcell.00245.2014. Epub 2015 Jan 14.

27.

Resistant hypertension in diabetes mellitus.

Bayliss G, Weinrauch LA, D'Elia JA.

Curr Diab Rep. 2014 Aug;14(8):516. doi: 10.1007/s11892-014-0516-y. Review.

PMID:
24965963
28.

Class I HDAC activity is required for renal protection and regeneration after acute kidney injury.

Tang J, Yan Y, Zhao TC, Gong R, Bayliss G, Yan H, Zhuang S.

Am J Physiol Renal Physiol. 2014 Aug 1;307(3):F303-16. doi: 10.1152/ajprenal.00102.2014. Epub 2014 May 7.

29.

Initiation of dialysis: a mini-review of a changing paradigm.

Bayliss G.

Cardiovasc Hematol Disord Drug Targets. 2014;14(3):165-9. Review.

PMID:
24720459
30.

Do biologic markers predict cardiovascular end points in diabetic end-stage renal disease? A prospective longitudinal study.

Bayliss GP, Weinrauch LA, Gleason RE, Lee AT, D'Elia JA.

Clin Kidney J. 2013 Dec;6(6):599-603. doi: 10.1093/ckj/sft116. Epub 2013 Sep 23.

31.

Immunosuppression after renal allograft failure: a survey of US practices.

Bayliss GP, Gohh RY, Morrissey PE, Rodrigue JR, Mandelbrot DA.

Clin Transplant. 2013 Nov-Dec;27(6):895-900. doi: 10.1111/ctr.12254. Epub 2013 Oct 11.

PMID:
24118389
32.

Class I histone deacetylase activity is required for proliferation of renal epithelial cells.

Tang J, Yan Y, Zhao TC, Bayliss G, Yan H, Zhuang S.

Am J Physiol Renal Physiol. 2013 Aug 1;305(3):F244-54. doi: 10.1152/ajprenal.00126.2013. Epub 2013 May 22.

33.

Sustained activation of EGFR triggers renal fibrogenesis after acute kidney injury.

Tang J, Liu N, Tolbert E, Ponnusamy M, Ma L, Gong R, Bayliss G, Yan H, Zhuang S.

Am J Pathol. 2013 Jul;183(1):160-72. doi: 10.1016/j.ajpath.2013.04.005. Epub 2013 May 15.

34.

Blocking the class I histone deacetylase ameliorates renal fibrosis and inhibits renal fibroblast activation via modulating TGF-beta and EGFR signaling.

Liu N, He S, Ma L, Ponnusamy M, Tang J, Tolbert E, Bayliss G, Zhao TC, Yan H, Zhuang S.

PLoS One. 2013;8(1):e54001. doi: 10.1371/journal.pone.0054001. Epub 2013 Jan 16.

35.

EGFR activity is required for renal tubular cell dedifferentiation and proliferation in a murine model of folic acid-induced acute kidney injury.

He S, Liu N, Bayliss G, Zhuang S.

Am J Physiol Renal Physiol. 2013 Feb 15;304(4):F356-66. doi: 10.1152/ajprenal.00553.2012. Epub 2012 Dec 19.

36.

Pathophysiology of obesity-related renal dysfunction contributes to diabetic nephropathy.

Bayliss G, Weinrauch LA, D'Elia JA.

Curr Diab Rep. 2012 Aug;12(4):440-6. doi: 10.1007/s11892-012-0288-1. Review.

PMID:
22638939
37.

Suramin alleviates glomerular injury and inflammation in the remnant kidney.

Liu N, He S, Tolbert E, Gong R, Bayliss G, Zhuang S.

PLoS One. 2012;7(4):e36194. doi: 10.1371/journal.pone.0036194. Epub 2012 Apr 27.

38.

The impact of a prior history of cardiovascular events on outcomes in patients on renal replacement therapy.

Bayliss G, Roshan B, Ventrapragada S, Weinrauch LA, Gleason RE, D' Elia JA.

Int J Cardiol. 2012 May 17;157(1):146-8. doi: 10.1016/j.ijcard.2012.03.026. Epub 2012 Mar 29. No abstract available.

PMID:
22464248
39.

Genetic or pharmacologic blockade of EGFR inhibits renal fibrosis.

Liu N, Guo JK, Pang M, Tolbert E, Ponnusamy M, Gong R, Bayliss G, Dworkin LD, Yan H, Zhuang S.

J Am Soc Nephrol. 2012 May;23(5):854-67. doi: 10.1681/ASN.2011050493. Epub 2012 Feb 23.

40.

Diabetic microvascular complications: possible targets for improved macrovascular outcomes.

D'Elia JA, Bayliss G, Roshan B, Maski M, Gleason RE, Weinrauch LA.

Int J Nephrol Renovasc Dis. 2011;4:1-15. doi: 10.2147/IJNRD.S14716. Epub 2010 Dec 22.

41.

An unusual presentation of hematuria.

Said FR, Griffith RC, Bayliss GP.

Kidney Int. 2011 Apr;79(8):923. doi: 10.1038/ki.2010.547. No abstract available.

42.

Minimal-change renal disease and Graves' disease: a case report and literature review.

Hasnain W, Stillman IE, Bayliss GP.

NDT Plus. 2011 Apr;4(2):96-8. doi: 10.1093/ndtplus/sfq213. Epub 2011 Jan 27.

43.

Dialysis in the poisoned patient.

Bayliss G.

Hemodial Int. 2010 Apr;14(2):158-67. doi: 10.1111/j.1542-4758.2009.00427.x. Epub 2010 Mar 19. Review.

PMID:
20337746
44.

Nocturnal versus conventional haemodialysis: some current issues.

Bayliss G, Danziger J.

Nephrol Dial Transplant. 2009 Dec;24(12):3612-7. doi: 10.1093/ndt/gfp491. Epub 2009 Sep 19. Review. No abstract available.

PMID:
19767631
45.

A pilot study to assess utility of changes in elements of the Diabetes Impact Management Scale in evaluating diabetic patients for progressive nephropathy.

Weinrauch LA, Bayliss G, Gleason RE, Lee AT, D'Elia JA.

Metabolism. 2009 Apr;58(4):492-6. doi: 10.1016/j.metabol.2008.11.005.

PMID:
19303969
46.

Utilization of an abbreviated diabetes impact management scale to assess change in subjective disability during a trial of pulsatile insulin delivery demonstrates benefit.

Weinrauch LA, Bayliss G, Gleason RE, Lee AT, D'Elia JA.

Metabolism. 2009 Apr;58(4):488-91. doi: 10.1016/j.metabol.2008.11.006.

PMID:
19303968
47.

Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys.

Crispín JC, Oukka M, Bayliss G, Cohen RA, Van Beek CA, Stillman IE, Kyttaris VC, Juang YT, Tsokos GC.

J Immunol. 2008 Dec 15;181(12):8761-6.

48.

Renal failure and abdominal pain as the presenting symptoms of a rare tumor of the aorta masquerading as a calcified plaque.

Bayliss G, Jacobs W, Williams M.

NDT Plus. 2008 Oct;1(5):316-8. doi: 10.1093/ndtplus/sfn101. Epub 2008 Jul 12.

49.

T cells and in situ cryoglobulin deposition in the pathogenesis of lupus nephritis.

Cohen RA, Bayliss G, Crispin JC, Kane-Wanger GF, Van Beek CA, Kyttaris VC, Avalos I, Yu CY, Tsokos GC, Stillman IE.

Clin Immunol. 2008 Jul;128(1):1-7. doi: 10.1016/j.clim.2008.04.004.

50.

The Case: an unknown toxin.

Farag YM, Bayliss GP, Singh AK.

Kidney Int. 2008 May;73(10):1201-2. doi: 10.1038/ki.2008.38. No abstract available.

Supplemental Content

Loading ...
Support Center